GLP-1 Weight Loss Results: Real Data from Clinical Trials

Quick Answer

The clinical trial results for GLP-1 medications are unambiguous: semaglutide (Wegovy) produces 14.9% average body weight loss; tirzepatide (Zepbound) produces up to 20.9%. Both are far beyond any previous weight loss medication. The results are reproducible across races, sexes, and geographic regions — these are not outlier findings.

Why the Trial Data Matters

There's a lot of testimonial content online about GLP-1 results — social media transformations, Reddit threads, and clinic before-and-afters. All of that has value, but it's subject to selection bias. Clinical trials eliminate that bias by randomizing thousands of patients and measuring everyone's outcome, not just the success stories.

The data below comes from peer-reviewed, randomized, placebo-controlled trials — the highest level of evidence in medicine.

Semaglutide: The STEP Trial Program

Novo Nordisk ran five major STEP trials for Wegovy (semaglutide 2.4 mg):

STEP 1 (n=1,961, no diabetes, 68 weeks)

Semaglutide group: -14.9% body weight
Placebo group: -2.4%
Net treatment difference: -12.4 percentage points

STEP 2 (n=1,210, type 2 diabetes, 68 weeks)

Semaglutide group: -9.6% body weight
(Confirms that diabetes status reduces efficacy somewhat)

STEP 3 (added intensive behavioral therapy, 68 weeks)

Semaglutide group: -16.0% body weight
(Lifestyle intervention amplifies GLP-1 results)

STEP 4 (continued vs. discontinued at week 20)

Patients who continued: further loss to -17.4% at week 68
Patients who switched to placebo: regained weight to -5% by week 68
This trial confirmed that weight regain begins immediately upon discontinuation

STEP 5 (long-term, 104 weeks)

Semaglutide group maintained -15.2% weight loss at 2 years
Confirms durable weight loss with continued treatment

Tirzepatide: The SURMOUNT Trial Program

Eli Lilly ran the SURMOUNT trials for Zepbound (tirzepatide):

SURMOUNT-1 (n=2,539, no diabetes, 72 weeks)

Dose	Avg. Weight Loss	% Losing ≥20%
5 mg	-15.0%	32%
10 mg	-19.5%	51%
15 mg	-20.9%	57%
Placebo	-3.1%	1%

SURMOUNT-2 (type 2 diabetes, 72 weeks)

15 mg tirzepatide: -14.7% weight loss

SURMOUNT-MMO (cardiovascular outcomes, ongoing)

Head-to-Head: Semaglutide vs. Tirzepatide

No major head-to-head trial has been published comparing these two medications for obesity specifically. The SURPASS-CVOT trial compared them for diabetes outcomes, and the SURMOUNT-5 trial (tirzepatide vs. semaglutide 2.4 mg in obesity) is completed with results expected in 2025.

Based on indirect comparison of trial data, tirzepatide appears to produce approximately 5–6 percentage points more weight loss on average. This is attributed to the dual GLP-1/GIP receptor activation.

Results Across Different Patient Groups

Clinical trials consistently show:

Women lose slightly more weight than men on semaglutide (sex difference ~1–2%)
Non-diabetic patients lose more than patients with type 2 diabetes
Results are consistent across racial groups — the STEP trials enrolled diverse populations with similar outcomes
Patients with higher starting BMI lose similar percentages but greater absolute weight

What These Results Mean in Practice

A 15–21% weight loss represents:

Reversal or improvement of obesity-related conditions (hypertension, sleep apnea, prediabetes)
Reduced joint pain and improved mobility
Improved lipid profile and blood pressure
Significant quality-of-life improvement

The SELECT trial (2023) demonstrated that semaglutide produced a 20% reduction in major cardiovascular events in people with obesity and established heart disease — making GLP-1 not just a weight loss tool but a cardiovascular medication.

See If You Qualify for GLP-1 Treatment

Bottom Line

GLP-1 weight loss results are not hype — they are among the most reproducible findings in recent pharmacology. Semaglutide produces ~15% loss, tirzepatide ~21%, in large trials across diverse populations. These results persist for years with continued treatment.